Literature DB >> 9184399

CD11b/CD18 mediates the neutrophil chemotactic activity of fibrin degradation product D domain.

T J Gross1, K J Leavell, M W Peterson.   

Abstract

Coagulation and fibrinolysis universally accompany tissue injury and repair. The accumulation of regionally generated fibrin degradation products (FDP) may modify the local inflammatory response. We have found FDP to be potent neutrophil chemotaxins. We separated plasmin FDP by chromatofocusing and found chemotactic activity limited to fractions containing the fibrinogen D domain (D-D dimer and D monomer). The bioactivity of the D-D dimer did not require an intact cross link site as removal of this sequence with puff adder venom or hypocalcemic plasmic digestion did not decrease chemotaxis. Peptide inhibition studies confirmed that the chemotactic region did not involve terminal gamma chain sequences or alpha chain RGD motifs. The internal gamma chain peptide KYGWTVFQKRLDGSV (P1), known to bind CD11b/CD18, exhibited concentration dependent chemotactic activity. Similarly, monoclonal antibodies directed against CD11b/CD18 blocked PMN migration to FDP without similar inhibition of chemotaxis to IL-8 or LTB4. Thus, neutrophil chemotaxis to FDP is mediated by interactions between the fibrinogen D domain and CD11b/CD18.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9184399

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  19 in total

1.  High preoperative plasma fibrinogen is an independent predictor of distant metastasis and poor prognosis in renal cell carcinoma.

Authors:  Jun Du; Jian-Hua Zheng; Xu-Sheng Chen; Qing Yang; Yan-Hui Zhang; Lei Zhou; Xin Yao
Journal:  Int J Clin Oncol       Date:  2012-05-19       Impact factor: 3.402

2.  Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo.

Authors:  Frank M Szaba; Stephen T Smiley
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

Review 3.  Extracellular Matrix-Based Strategies for Immunomodulatory Biomaterials Engineering.

Authors:  Andrew T Rowley; Raji R Nagalla; Szu-Wen Wang; Wendy F Liu
Journal:  Adv Healthc Mater       Date:  2019-02-04       Impact factor: 9.933

4.  Provisional Matrix Deposition in Hemostasis and Venous Insufficiency: Tissue Preconditioning for Nonhealing Venous Ulcers.

Authors:  Tony J Parker; James A Broadbent; Jacqui A McGovern; Daniel A Broszczak; Christina N Parker; Zee Upton
Journal:  Adv Wound Care (New Rochelle)       Date:  2015-03-01       Impact factor: 4.730

Review 5.  Fibrin-based biomaterials: modulation of macroscopic properties through rational design at the molecular level.

Authors:  Ashley C Brown; Thomas H Barker
Journal:  Acta Biomater       Date:  2013-09-19       Impact factor: 8.947

Review 6.  Contribution of platelets, the coagulation and fibrinolytic systems to cutaneous wound healing.

Authors:  Aman Opneja; Sargam Kapoor; Evi X Stavrou
Journal:  Thromb Res       Date:  2019-05-02       Impact factor: 3.944

7.  Neutrophils, nitric oxide synthase, and mutations in the mutatect murine tumor model.

Authors:  J K Sandhu; H F Privora; G Wenckebach; H C Birnboim
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

Review 8.  Molecular Aspects of Wound Healing and the Rise of Venous Leg Ulceration: Omics Approaches to Enhance Knowledge and Aid Diagnostic Discovery.

Authors:  Daniel A Broszczak; Elizabeth R Sydes; Daniel Wallace; Tony J Parker
Journal:  Clin Biochem Rev       Date:  2017-02

9.  Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells.

Authors:  Melanie Rolli; Emilia Fransvea; Jan Pilch; Alan Saven; Brunhilde Felding-Habermann
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-21       Impact factor: 11.205

10.  Complement activation triggered by chondroitin sulfate released by thrombin receptor-activated platelets.

Authors:  O A Hamad; K N Ekdahl; P H Nilsson; J Andersson; P Magotti; J D Lambris; B Nilsson
Journal:  J Thromb Haemost       Date:  2008-05-22       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.